Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Michèle Hoffmann, Yara Banz, Jörg Halter, Jacqueline Schoumans, Joëlle Tchinda, Ulrike Bacher, Thomas Pabst
Donor cell leukemia (DCL) is a rare complication after allogeneic hematopoietic stem cell transplantation (HSCT) accounting for 0.1% of relapses and presenting as secondary leukemia of donor origin. Distinct in phenotype and cytogenetics from the original leukemia, DCL's clinical challenge lies in its late onset. Its origin is affected by donor cell anomalies, transplant environment, and additional mutations. A 43-year-old woman, treated for early stage triple-negative breast cancer, developed mixed-phenotype acute leukemia (MPAL), 12 years later...
April 5, 2024: Current Oncology
#2
REVIEW
Xinliang Chen, Chaonan Liu, Junping Wang, Changhong Du
Despite breakthroughs in modern medical care, the incidence of cardiovascular disease (CVD) is even more prevalent globally. Increasing epidemiologic evidence indicates that emerging cardiovascular risk factors arising from the modern lifestyle, including psychosocial stress, sleep problems, unhealthy diet patterns, physical inactivity/sedentary behavior, alcohol consumption, and tobacco smoking, contribute significantly to this worldwide epidemic, while its underpinning mechanisms are enigmatic. Hematological and immune systems were recently demonstrated to play integrative roles in linking lifestyle to cardiovascular health...
April 19, 2024: Cells
#3
JOURNAL ARTICLE
Christopher J Trindade, Xiaoping Sun, Dragan Maric, Sachein Sharma, Hirsh D Komarow, Christopher S Hourigan, Amy Klion, Irina Maric
BACKGROUND: Flow cytometry has been widely used to study immunophenotypic patterns of maturation of most hematopoietic lineages in normal human bone marrow aspirates, thus allowing identification of changes in patterns in many myeloid malignancies. Eosinophils play an important role in a wide variety of disorders, including some myeloid neoplasms. However, changes in flow cytometric immunophenotypic patterns during normal and abnormal bone marrow eosinophilopoiesis have not been well studied...
April 26, 2024: Cytometry. Part B, Clinical Cytometry
#4
Polina Bellman, Jesus D Gonzalez-Lugo, Moazzam Shahzad, Muhammad Kashif Amin, Muhammad Fareed Khalid, Nahid Suleman, Nausheen Ahmed, Anurag K Singh, Abdulraheem Yacoub, Da Zhang, Joseph P McGuirk, Muhammad Umair Mushtaq
Vacuoles, E1 syndrome, X-linked, autoinflammatory, somatic (VEXAS) syndrome is a chronic inflammatory disorder that affects various organ systems. It is associated with hematologic malignancies and is generally refractory to therapies. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) may be considered for selected patients. We report a case wherein systemic and hematological manifestations completely resolved in a patient with VEXAS and associated myelodysplastic syndrome (MDS), following the administration of fludarabine and cyclophosphamide as part of the preparation for allo-HSCT...
2024: Frontiers in Oncology
#5
REVIEW
Jiawen Huang, Qian Yang, Wen Wang, Juan Huang
Chimeric antigen receptor (CAR) T cell therapy has transformed cancer immunotherapy. However, significant challenges limit its application beyond B cell-driven malignancies, including limited clinical efficacy, high toxicity, and complex autologous cell product manufacturing. Despite efforts to improve CAR T cell therapy outcomes, there is a growing interest in utilizing alternative immune cells to develop CAR cells. These immune cells offer several advantages, such as major histocompatibility complex (MHC)-independent function, tumor microenvironment (TME) modulation, and increased tissue infiltration capabilities...
2024: Frontiers in Immunology
#6
JOURNAL ARTICLE
Zhipeng Li, Jing Wang, Lei Deng, Ximin Liu, Fanjun Kong, Yuerong Zhao, Yixi Hou, Fang Zhou
INTRODUCTION: Chimerism is closely correlated with disease relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, chimerism rate is dynamic changes, and the sensitivity of different chimerism requires further research. METHODS: To investigate the predictive value of distinct chimerism for relapse, we measured bone marrow (BM), peripheral blood (PB), and T-cell (isolated from BM) chimerism in 178 patients after allo-HSCT. RESULTS: Receiver operating characteristic (ROC) curve showed that T-cell chimerism was more suitable to predict relapse after allo-HSCT compared with PB and BM chimerism...
2024: Frontiers in Immunology
#7
JOURNAL ARTICLE
Rashin Mohseni, Pouya Mahdavi Sharif, Abbas Khosravi, Ahmad Reza Taheri, Maryam Behfar, Morteza Zarrabi, Leila Jafari, Fahimeh Jafari, Zeynab Nikfetrat, Parisa Naji, Amir Ali Hamidieh
BACKGROUND: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative strategy against a variety of malignant and nonmalignant disorders. However, acute and chronic graft-versus-host disease (aGVHD and cGVHD, respectively) commonly complicate this approach, culminating in substantial morbidities and mortalities. The integumentary system is the preponderant organ involved in cGVHD, and its response to existing treatments, including well-versed immunosuppressants and novel targeted therapies, is not desirable...
April 23, 2024: Transplantation and cellular therapy
#8
JOURNAL ARTICLE
Julien De Greef, Dina Averbuch, Laura Tondeur, Amélie Duréault, Tsila Zuckerman, Xavier Roussel, Christine Robin, Alienor Xhaard, Simona Pagliuca, Yves Beguin, Carmen Botella-Garcia, Nina Khanna, Amandine Le Bourgeois, Jens Van Praet, Aloysius Ho, Nicolaus Kröger, Sophie Ducastelle Leprêtre, Damien Roos-Weil, Mahmoud Aljurf, Nicole Blijlevens, Igor Wolfgang Blau, Kristina Carlson, Matthew Collin, Arnold Ganser, Alban Villate, Johannes Lakner, Sonja Martin, Arnon Nagler, Ron Ram, Anna Torrent, Maria Stamouli, Malgorzata Mikulska, Lidia Gil, Lotus Wendel, Gloria Tridello, Nina Knelange, Rafael de la Camara, Olivier Lortholary, Arnaud Fontanet, Jan Styczynski, Johan Maertens, Julien Coussement, David Lebeaux
OBJECTIVES: Nocardiosis is a rare but life-threatening infection after hematopoietic cell transplantation (HCT). We aimed at identifying risk factors for nocardiosis after allogeneic HCT and clarifying the effect of trimethoprim-sulfamethoxazole prophylaxis on its occurrence. METHODS: We performed a retrospective multicenter case-control study of patients diagnosed with nocardiosis after allogeneic HCT between January 2000 and December 2018. For each case, two controls were matched by center, transplant date, and age group...
April 23, 2024: Journal of Infection
#9
JOURNAL ARTICLE
Alison Moe, Aditya Rayasam, Garrett Sauber, Ravi K Shah, Ashley Doherty, Cheng-Yin Yuan, Aniko Szabo, Bob M Moore Ii, Marco Colonna, Weiguo Cui, Julian Romero, Anthony E Zamora, Cecilia J Hillard, William R Drobyski
Neuroinflammation is a recognized complication of immunotherapeutic approaches such as immune checkpoint inhibitor treatment, chimeric antigen receptor therapy, and graft versus host disease (GVHD) occurring after allogeneic hematopoietic stem cell transplantation. While T cells and inflammatory cytokines play a role in this process, the precise interplay between the adaptive and innate arms of the immune system that propagates inflammation in the central nervous system remains incompletely understood. Using a murine model of GVHD, we demonstrate that type 2 cannabinoid receptor (CB2R) signaling plays a critical role in the pathophysiology of neuroinflammation...
April 25, 2024: Journal of Clinical Investigation
#10
JOURNAL ARTICLE
Kumiyo Tazoe, Naonori Harada, Yosuke Makuuchi, Masatomo Kuno, Teruhito Takakuwa, Hiroshi Okamura, Asao Hirose, Mika Nakamae, Mitsutaka Nishimoto, Yasuhiro Nakashima, Hideo Koh, Masayuki Hino, Hirohisa Nakamae
Myelodysplastic syndrome (MDS) is well known to be complicated by systemic inflammatory autoimmune disease (SIADs). However, it remains unclear how the prognosis after allogenic hematopoietic stem cell transplantation (allo-HSCT) in patients with MDS is impacted by SIADs that occur before allo-HSCT. Therefore, we hypothesized that SIADs before allo-HSCT may be a risk factor for negative outcomes after allo-HSCT in patients with MDS. We conducted a single-center, retrospective, observational study of sixty-nine patients with MDS or chronic myelomonocytic leukemia who underwent their first allo-HCT...
April 25, 2024: Annals of Hematology
#11
JOURNAL ARTICLE
Olivier Veilleux, Francisco Socola, Sally Arai, Matthew J Frank, Laura Johnston, Robert Lowsky, Judith Shizuru, Everett Meyer, Lori Muffly, Andrew R Rezvani, Parveen Shiraz, Surbhi Sidana, Saurabh Dahiya, David B Miklos, Robert S Negrin, Wen-Kai Weng
Autologous hematopoietic cell transplantation (AHCT) is often used as a consolidation for patients with peripheral T-cell lymphomas (PTCLs) due to the poor prognosis associated with this heterogenous group of disorders. However, a significant number of patients will experience post-AHCT disease relapse. Here, we report a retrospective study of consecutive 124 patients with PTCLs who underwent AHCT from 2008 to 2020. With a median follow-up of 6.01 years following AHCT, 49 patients (40%) experienced disease relapse...
April 25, 2024: American Journal of Hematology
#12
REVIEW
Tingting Zhang, Yicheng Zhang, Jia Wei
Chimeric antigen receptor (CAR) -T cell therapy has entered the breakthrough era, characterized by a blend of therapeutic opportunities and challenges. With the integration of genome-editing technology, CAR-T cells will be empowered to become super warriors in eradicating tumor cells and attacking various tumors, including T-cell malignancies and acute myeloid leukemia. Notably, the optimization of CAR-T cells, including efficacy, safety, and manufacturing speed, coupled with other therapeutic strategies such as radiotherapy, hematopoietic stem cell transplantation, small-molecule inhibitors, and bispecific antibodies, could revolutionize the therapeutic landscape of tumors...
2024: Frontiers in Immunology
#13
JOURNAL ARTICLE
Saiphon Poldee, Chanatip Metheetrairut, Wichit Suthammarak, Kongtana Trakarnsanga
At present, the numbers of cultured erythroid cells obtained from culture systems are not on a scale that can be used for therapeutics since the cultured erythroid cells have limited proliferation capacity. Stromal cells are believed to play important roles during erythropoiesis. Our previous study shows that factors secreted by stromal cells enhance the proliferation capacity of adult erythroid cells in the culture system. Among the identified factors, angiotensinogen is one of the most abundant proteins secreted by the stromal cells...
June 2024: MethodsX
#14
JOURNAL ARTICLE
Yiman Liu, Qinglan Li, Lele Song, Chujie Gong, Sylvia Tang, Krista A Budinich, Ashley Vanderbeck, Kaeli M Mathias, Gerald B Wertheim, Son C Nguyen, Riley Outen, Eric F Joyce, Ivan Maillard, Liling Wan
Gain-of-function mutations in the histone acetylation 'reader' ENL, found in AML and Wilms tumor, are known to drive condensate formation and gene activation in cellular systems. However, their role in tumorigenesis remains unclear. Using a conditional knock-in mouse model, we show that mutant ENL perturbs normal hematopoiesis, induces aberrant expansion of myeloid progenitors, and triggers rapid onset of aggressive AML. Mutant ENL alters developmental and inflammatory gene programs in part by remodeling histone modifications...
April 24, 2024: Cancer Discovery
#15
JOURNAL ARTICLE
Sara Benchikh, Soro Somda Georgina Charlène, Amale Bousfiha, Lunda Razoki, Jamila Aboulfaraj, Latifa Zarouf, Adil El Hamouchi, Abderrahim Malki, Sanaa Nassereddine
Chronic myeloid leukemia (CML) is a neoplastic disease of genetic origin resulting from clonal proliferation of hematopoietic stem cells (HSCs). The reciprocal translocation t(9;22)(q34;q11) is the main chromosomal abnormality involved in this pathology, usually detected by conventional cytogenetics. This article aims to investigate the epidemiological, cytogenetic, therapeutic, and clinical characteristics of Moroccan patients with CML. This research represents the first large-scale study of CML patients in Morocco and was carried out at Institut Pasteur of Morocco...
April 24, 2024: Annals of Hematology
#16
REVIEW
Shiyu Xiao, Hongxia Chen, Yunpeng Bai, Zhong-Yin Zhang, Yan Liu
INTRODUCTION: Phosphatase of regenerating liver (PRL) family proteins, also known as protein tyrosine phosphatase 4A (PTP4A), have been implicated in many types of cancers. The PRL family of phosphatases consists of three members, PRL1, PRL2, and PRL3. PRLs have been shown to harbor oncogenic potentials and are highly expressed in a variety of cancers. Given their roles in cancer progression and metastasis, PRLs are potential targets for anticancer therapies. However, additional studies are needed to be performed to fully understand the roles of PRLs in blood cancers...
April 23, 2024: Expert Opinion on Therapeutic Targets
#17
REVIEW
Navigating the Tumor Microenvironment: Mesenchymal Stem Cell-Mediated Delivery of Anticancer Agents.
Muhammad Ahsan Waqar, Muhammad Zaman, Muhammad ShafeeqUrRahman, Rabeel Khan, Imtiaz Majeed
Scientific knowledge of cancer has advanced greatly throughout the years, with most recent studies findings includes many hallmarks that capture disease's multifaceted character. One of the novel approach utilized for the delivery of anti-cancer agents includes mesenchymal stem cell mediated drug delivery. Mesenchymal stem cells (MSCs) are non-hematopoietic progenitor cells that may be extracted from bone marrow, tooth pulp, adipose tissue and placenta/umbilical cord blood dealing with adult stem cells. MSCs are mostly involved in regeneration of tissue, they have also been shown to preferentially migrate to location of several types of tumor in-vivo ...
April 23, 2024: Journal of Drug Targeting
#18
REVIEW
Costanza Rossi, Alessandro Buizza, Giuseppe Alessio, Massimiliano Borselli, Andrea Taloni, Adriano Carnevali, Giovanna Carnovale Scalzo, Andrea Lucisano, Vincenzo Scorcia, Giuseppe Giannaccare
Ocular complications can occur in up to 90% of patients with blood malignancies. Such complications range from direct infiltration to local hemostatic imbalance and treatment-related toxicity. This narrative review is based on a systematic computerized search of the literature conducted until January 2024 and examines the common ocular complications associated with blood cancers. Ocular complications from primary disease include mass effects from ocular adnexal lymphomas and intraocular lymphomas, with B-cell lymphomas accounting for 95% of primary ocular presentations...
March 28, 2024: Hematology Reports
#19
JOURNAL ARTICLE
Yahan Li, Fansheng Kong, Guanchen Bai, Yujie Jiang, Wenlu Zhang, Xue Sun, Xiaohui Sui, Ying Li, Mei Ding, Dai Yuan, Xin Wang, Xiaosheng Fang
BACKGROUND: Eltrombopag has demonstrated efficacy in treating low platelet (PLT) levels, but it remains unclear whether eltrombopag can promote PLT engraftment after hematopoietic stem cell transplantation (HSCT). METHODS: Forty-one HSCT patients received eltrombopag 50 mg/d from +1 day until PLT >50 × 109 /L or 1 month after HSCT. Fifty-one patients in the same period received thrombopoietin (TPO) to promote PLT graft after HSCT and served as a control group...
2024: Frontiers in Immunology
#20
JOURNAL ARTICLE
Hui Chen, Xiangna Guan, Chi He, Tingting Lu, Xingyu Lin, Xuebin Liao
INTRODUCTION: Hematopoietic progenitor kinase 1 (HPK1), a 97-kDa serine/threonine Ste20-related protein kinase, functions as an intracellular negative regulator, primarily in hematopoietic lineage cells, where it regulates T cells, B cells, dendritic cells and other immune cells. Loss of HPK1 kinase activity results in exacerbated cytokine secretion, enhanced T cell signaling, improved viral clearance, and thus increased restraint of tumor growth. These findings highlight HPK1 as a promising target for immuno-oncology treatments, culminating in the advancement of candidate compounds targeting HPK1 to clinical trials by several biotech enterprises...
April 22, 2024: Expert Opinion on Therapeutic Targets
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
